Table 3. Phase-III data for bevacizumab in adjuvant setting and recurrent ovarian cancer.

TRIAL	ARMS	Setting	PFS (HR, p value)	OS (HR, p value)
ICON 7 [21] N = 1528	CP versus CP + B → B (7.5 mg/kg) 12 cycles	Adjuvant	At 36 months follow-up 17.4 versus 19.8 [0.87; 0.004]	Restricted mean survival time 44.6 versus 44.5 p = 0.85
GOG 218 [20] N = 1873	CP versus CP + B versus CP + B → B (15 mg/kg) 22 cycles	Adjuvant	10.3 versus 11.2 versus 14.1 [0.908; 0.16] [0.717; < 0.001]	39.3 versus 38.7 versus 39.7 [1.036; 0.76] [0.915; 0.45]
OCEANS [23] n = 484	CG + placebo versus CG + B	Recurrent ovarian cancer	8.4 versus 12.4 [0.484; < 0.0001]	33.7c versus 33.4c [0.960; 0.736]
AURELIA [24] n = 361	CT (PLD, P or Top) versus CT + Bev	Recurrent ovarian cancer	3.4 versus 6.7 [0.48; < 0.001]	13.3 versus 16.6 [0.85; 0.174]

CP – carboplatin and paclitaxel, B – Bevacizumab, CG – carboplatin and gemcitabine,

CT – chemotherapy, PLD – liposomal doxorubicin, P – pacliltaxel, top – topotecan,

PFS – progression-free survival, OS – overall survival, HR – hazard ratio.